Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.

*Due to the nature of post-marketing adverse event reports, some of the investigations remain ongoing and therefore may be subject to change. For more information, please see the FAQs.